Novo Nordisk's Cyber Incident Clouds Pill Progress as Medicare Catalyst Nears

Novo Nordisk faces a data breach and stock slump, but its oral Wegovy pill, UK approval, and looming Medicare expansion signal strong operational momentum.

For Novo Nordisk, the past week has been a study in contrasts. Operations are humming along—the oral version of Wegovy is racking up millions of prescriptions, a key UK approval landed, and a major Medicare expansion is on the horizon. Yet the stock closed Friday at €38.03, a painful 46% below its 52-week high of €70.13, and investors now have a new worry: a data breach that exposed patient information from clinical trials.

The cybersecurity incident, disclosed on Thursday, saw unauthorized access to internal systems. Novo Nordisk immediately isolated certain networks as a precautionary measure, and while it stresses that core business continues normally, the breach has dampened sentiment. Externally, investigators are probing the attack. The company has begun notifying affected individuals and is cooperating with authorities. The full scope of the data theft—and any potential regulatory penalties—will define the near-term risk profile for the stock.

But the negative headlines mask a string of operational wins that are quietly reshaping the company’s outlook. The oral Wegovy pill—already a record-breaking launch in the US—generated over three million prescriptions in its first five months. Crucially, two-thirds of those patients are new to GLP-1 therapy, meaning the pill is expanding the market rather than cannibalising the injectable version. Management describes it as the strongest US pharma launch by volume.

International momentum is building too. On June 11, the UK's medicines regulator authorised the Wegovy pill, and an EU approval is expected shortly after the European Medicines Agency issued a positive opinion in May. Together with the July 1, 2026 start of Medicare coverage for obesity patients—who will pay just $50 a month for Wegovy—the volume catalyst is becoming tangible. That government program alone could drive a structural demand shift.

Rival Eli Lilly has its own oral contender, Foundayo, which won FDA approval in April 2026. Lilly’s pill has the convenience of no food or drink restrictions, but its early uptake has been sluggish—only 20,000 prescriptions in the first few weeks. Novo Nordisk’s CEO Mike Doustdar points to superior efficacy: the Wegovy pill delivered a 16.6% weight loss in studies, against 12.4% for Lilly’s product. The company also has a strong brand advantage and first-mover scale.

Pipeline progress adds to the picture. The REIMAGINE phase 3 trials showed that CagriSema—a combination of semaglutide and cagrilintide—met all primary endpoints in type 2 diabetes patients, significantly reducing blood sugar and body weight. The FDA is expected to decide on CagriSema for weight loss in the fourth quarter of 2026. One blemish: in a head-to-head trial, CagriSema achieved 23% weight loss versus 25.5% for Lilly’s Zepbound, missing the mark slightly.

Despite these positives, the bears remain fixated on pricing pressure and competition. Novo Nordisk’s 2026 guidance calls for a 4% to 12% decline in revenue and profit on a currency-adjusted basis, which has weighed heavily on market sentiment. The company has been buying back shares—nearly 19 million so far this year—but that has done little to stem the slide. Analysts are cautious: the consensus of 23 experts rates the stock "Neutral" with an average price target of around 312 Danish kroner.

For the stock to break out of its funk, proof will have to come from execution. The Medicare program begins in July, providing hard prescription data that could finally shift the narrative. With the shares trading at roughly €38, the positive catalysts are stacking up—but the cybersecurity breach and continued operational uncertainty mean the burden of proof now rests squarely with Novo Nordisk’s management.